WSP.TO 2.79COST -9.67TECK.B.TO -0.01ORCL 4.74SHOP.TO -0.2CDNS -12.175BRK.B -2.1ARGT -0.39
Amgen Inc. (AMGN)

NASDAQ:AMGN

Amgen Inc. (AMGN)

437.23
-6.89 (1.55%)
as of Sep 4, 2026, 8:00:00 pm Market Open.
107 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 4, 2026, 12:00 am

This summary was created by AI, based on 16 opinions in the last 12 months.

Amgen Inc. is a highly regarded biotech company with a robust portfolio, showing strong earnings and a promising pipeline. Experts note that the company has 15 products experiencing double-digit sales growth, particularly highlighting the potential of their GLP-1 drug, which is currently in phase 3 testing. Analysts have given positive reviews, emphasizing Amgen's solid management and stable dividend yields ranging from 3.23% to 3.46%. Despite some experts indicating concerns about the narrative surrounding Amgen, the technicals suggest it is undervalued, especially compared to its performance in the biotech sector and its historical position as one of the oldest firms in the industry. The general sentiment is that holding onto this stock could yield favorable returns in the long term, particularly as the biotech space is expected to outperform more defensive market areas in the coming years.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
Gilead,GILD
TOP PICK

Amgen Inc.(AMGN)

Aug 13, 2004
Likes the health-care sector. One of the top companies. Has underperformed for a long time, but they are willing to be patient.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$54.36

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Aug 13, 2004
A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that.
Photo of Samuel D. IsalySamuel D. Isaly
Owned
Unlock Rating
$54.36

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 16, 2004
Under a cloud. Driven down because of generic drugs and imports from Canada. Medicare will be onerous. Powerful balance sheet.
Photo of Alan BlakeAlan Blake
Owned
Unlock Rating
$55.73

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

May 14, 2004
Health care should outperform in a rising interest rate environment. A premier company. Likes the pipeline that it has. Out-of-favor right now.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$56.65

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

May 11, 2004
(A top pick in Feb/04. Down a bit.) This sector has great prospects on a going forward basis but will be volatile on a short-term basis. A leader in their field. Good growth prospects.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$57.14

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Apr 02, 2004
Photo of Nicholas SargenNicholas SargenUnlock Rating
$59.51

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Mar 09, 2004
A leading biotech company. Trading at 22 X next year's earnings. Pretty cheap for this quality of a company.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$62.76

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Dec 29, 2003
A very mature biotech company. Expects about 10/15% revenue growth and about 20/25% earnings growth. Trading at a low multiple.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$61.87

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Nov 03, 2003
(A top pick July 15/03. Down 13.7%.) Sold the stock in the summer.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$61.15

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Nov 03, 2003
Has made some good acquisitions in the last couple of years, which has propped up their product line. 25 X next year's earnings.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$61.19

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Amgen Inc.(AMGN)

Oct 22, 2003
They don't have the problem of drugs going off patent. The stock can go much higher. Dropping currently because the sector is pulling it down.
Photo of Paul O'NeilPaul O'Neil
No
Unlock Rating
$60.30

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Amgen Inc.(AMGN)

Jul 22, 2003
Was a top pick on Jun 4/03. Up 7%.) The leader in bio techs. Has grown its earnings every year since 1994.
Photo of David BurrowsDavid BurrowsUnlock Rating
$68.93

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 15, 2003
A lot of drug products in the pipeline. Cash flow is growing.
Photo of David BurrowsDavid BurrowsUnlock Rating
$71.54

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jul 02, 2003
Has made money every year going back to 1994. Good cash flow.
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$67.21

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Amgen Inc.(AMGN)

Jun 04, 2003
A safe way of investing in biotechs. Has held up through poor periods. Has a broad pipeline of products.
Photo of David BurrowsDavid BurrowsUnlock Rating
$64.49

Stock price when the opinion was issued

$437.23

As of Sep 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 136 to 150 of 166 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NXE.TO 0.16$14.89
ATD.TO 0.09$82
T.TO -0.01$13.39
KKR -2.03$107.73
CSU.TO -17.42$3023.96

Today's Top Picks

WSP.TO 2.79$186.86
COST -9.67$915.74
TECK.B.T… -0.01$13.39
ORCL 4.74$158.78
SHOP.TO -0.2$200.76

Popular Articles

Latest Sell Signals

LULU -21.16$100.61
CVX -2.72$208.6
ZQQ.TO 0.46$199.22
SOXX 17.66$519.86
AAPL -8.24$319.97

Most Recent Experts

Brian Madden

Brian Madden

First Avenue Investment Counsel

Kim Bolton

Kim Bolton

Black Swan Dexteritas

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like